Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2

Background: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is not well known. Aim: To assess the safety profile and effectiveness of 12 weeks of treatment with Vildagliptin for glycemic control in T2D...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Godoy J,Gonzalo, Gutiérrez,Vicente, Montecinos,Mario, Yenes,Alejandro
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2015
Materias:	Adamantane Hypoglycemic agents Pragmatic clinical trials as topics
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100008
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872015000100008
record_format	dspace
spelling	oai:scielo:S0034-988720150001000082015-08-11Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2Godoy J,GonzaloGutiérrez,VicenteMontecinos,MarioYenes,Alejandro Adamantane Hypoglycemic agents Pragmatic clinical trials as topics Background: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is not well known. Aim: To assess the safety profile and effectiveness of 12 weeks of treatment with Vildagliptin for glycemic control in T2D Chilean patients with a poor glycemic control. Patients and Methods: Retrospective assessment of the effects of Vildagliptin treatment during 12 weeks in 103 T2D patients aged 29 to 92 years (47% males). The main outcomes were changes in glycosylated hemoglobin and the occurrence of adverse effects. Results: After 12 weeks of Vildagliptin use, glycosylated hemoglobin decreased from 8.3 ± 1.4 to 7.2 ± 1.1% (p < 0.01). Fasting plasma glucose and the number of hypoglycemic events also decreased significantly. No significant weight change was observed. The treatment had good compliance, tolerance and patient satisfaction. Conclusions: Vildagliptin treatment reduced glycosylated hemoglobin by 1.1% and was well tolerated in this group of diabetic patients.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.143 n.1 20152015-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100008es10.4067/S0034-98872015000100008
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Adamantane Hypoglycemic agents Pragmatic clinical trials as topics
spellingShingle	Adamantane Hypoglycemic agents Pragmatic clinical trials as topics Godoy J,Gonzalo Gutiérrez,Vicente Montecinos,Mario Yenes,Alejandro Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
description	Background: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is not well known. Aim: To assess the safety profile and effectiveness of 12 weeks of treatment with Vildagliptin for glycemic control in T2D Chilean patients with a poor glycemic control. Patients and Methods: Retrospective assessment of the effects of Vildagliptin treatment during 12 weeks in 103 T2D patients aged 29 to 92 years (47% males). The main outcomes were changes in glycosylated hemoglobin and the occurrence of adverse effects. Results: After 12 weeks of Vildagliptin use, glycosylated hemoglobin decreased from 8.3 ± 1.4 to 7.2 ± 1.1% (p < 0.01). Fasting plasma glucose and the number of hypoglycemic events also decreased significantly. No significant weight change was observed. The treatment had good compliance, tolerance and patient satisfaction. Conclusions: Vildagliptin treatment reduced glycosylated hemoglobin by 1.1% and was well tolerated in this group of diabetic patients.
author	Godoy J,Gonzalo Gutiérrez,Vicente Montecinos,Mario Yenes,Alejandro
author_facet	Godoy J,Gonzalo Gutiérrez,Vicente Montecinos,Mario Yenes,Alejandro
author_sort	Godoy J,Gonzalo
title	Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
title_short	Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
title_full	Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
title_fullStr	Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
title_full_unstemmed	Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
title_sort	evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
publisher	Sociedad Médica de Santiago
publishDate	2015
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100008
work_keys_str_mv	AT godoyjgonzalo evaluaciondelperfildeeficaciayseguridaddevildagliptinaenvidarealdepacienteschilenoscondiabetesmellitustipo2 AT gutierrezvicente evaluaciondelperfildeeficaciayseguridaddevildagliptinaenvidarealdepacienteschilenoscondiabetesmellitustipo2 AT montecinosmario evaluaciondelperfildeeficaciayseguridaddevildagliptinaenvidarealdepacienteschilenoscondiabetesmellitustipo2 AT yenesalejandro evaluaciondelperfildeeficaciayseguridaddevildagliptinaenvidarealdepacienteschilenoscondiabetesmellitustipo2
_version_	1718436799151341568

Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2

Ejemplares similares